These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6602269)

  • 1. High dose systemic methotrexate-associated acute neurologic dysfunction.
    Packer RJ; Grossman RI; Belasco JB
    Med Pediatr Oncol; 1983; 11(3):159-61. PubMed ID: 6602269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.
    Kiu MC; Liaw CC; Yang TS; Lai GM; Hsi SN; Lu CS
    Anticancer Drugs; 1994 Aug; 5(4):480-2. PubMed ID: 7949255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
    Allen JC; Rosen G
    Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The results of using high-dose methotrexate in treating osteogenic sarcoma].
    Perevodchikova NI; Eremina LA; Manziuk LV; Siniukov PA; Fedenko AN; Singin AS; Moldovanova LK
    Vopr Onkol; 1990; 36(6):667-71. PubMed ID: 2378085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient encephalopathy during the late course of treatment with high-dose methotrexate.
    Fritsch G; Urban C
    Cancer; 1984 May; 53(9):1849-51. PubMed ID: 6584197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient neurologic disturbances induced by high-dose methotrexate treatment.
    Jaffe N; Takaue Y; Anzai T; Robertson R
    Cancer; 1985 Sep; 56(6):1356-60. PubMed ID: 3875390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
    Camitta BM; Holcenberg JS
    Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma.
    Goorin A; Strother D; Poplack D; Letvak LA; George M; Link M
    Med Pediatr Oncol; 1995 Jun; 24(6):362-7. PubMed ID: 7715542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient case involving high-dose methotrexate followed by leucovorin rescue.
    Alsop JA
    Am J Hosp Pharm; 1978 Feb; 35(2):127. PubMed ID: 305201
    [No Abstract]   [Full Text] [Related]  

  • 11. Normal computed tomograms of the brain in osteosarcoma patients treated with high-dose methotrexate.
    Bowles D; Pratt C; Evans W; Price RA; Coburn T
    Cancer; 1981 Apr; 47(7):1762-5. PubMed ID: 6971702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
    Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
    Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
    [No Abstract]   [Full Text] [Related]  

  • 13. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
    Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
    Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.
    Jaffe N; Paed D; Farber S; Traggis D; Geiser C; Kim BS; Das L; Frauenberger G; Djerassi I; Cassady JR
    Cancer; 1973 Jun; 31(6):1367-73. PubMed ID: 4541163
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma.
    Jaffe N; Traggis D; Cassady JR; Filler RM; Watts H; Frei E
    Int J Radiat Oncol Biol Phys; 1977; 2(3-4):261-6. PubMed ID: 301137
    [No Abstract]   [Full Text] [Related]  

  • 19. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.
    Shuper A; Stark B; Kornreich L; Cohen IJ; Aviner S; Steinmetz A; Stein J; Goshen Y; Yaniv I
    J Child Neurol; 2000 Sep; 15(9):573-80. PubMed ID: 11019787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily profiles of plasma phenylalanine and tyrosine in patients with osteogenic sarcoma during treatment with high-dose methotrexate-citrovorum rescue.
    Hilton MA; Bertolone S; Patel CC
    Med Pediatr Oncol; 1989; 17(4):265-70. PubMed ID: 2787470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.